Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems (NYSE: INSP) announced preliminary revenue results for Q4 and full year 2022, projecting revenues of $137.5 million to $137.9 million for Q4, reflecting a 76% increase year-over-year, and $407.5 million to $407.9 million for the full year, a 75% increase from 2021. The company activated 61 new medical centers and created 16 new sales territories in Q4. The full financial results will be reported on February 7, 2023. Inspire's therapy, which is FDA-approved for obstructive sleep apnea, continues to gain traction in the U.S. and Europe.
Inspire Medical Systems (NYSE: INSP) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. Pacific Time. The event will take place at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation will be available, with a replay accessible for two weeks on Inspire's Investor website. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, including its FDA-approved Inspire therapy, a neurostimulation technology for moderate to severe cases.
Summary not available.
Inspire Medical Systems (NYSE: INSP) announced its participation in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at the Lotte New York Palace Hotel. The management team will present at 3:30 p.m. ET, with a live webcast available for viewers. Inspire focuses on innovative, minimally invasive solutions for obstructive sleep apnea and is recognized for its Inspire therapy, the first FDA-approved neurostimulation technology for moderate to severe cases. A replay of the presentation will be accessible on Inspire's investor website for two weeks afterward.
Inspire Medical Systems (NYSE: INSP) announced that its management team will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 2:25 p.m. ET. The event will take place at the Lotte New York Palace Hotel. A live webcast of the presentation will be available and can be accessed through Inspire’s investor website, which will also host a replay for two weeks afterwards. Inspire is known for its innovative solutions for obstructive sleep apnea, including the first FDA-approved neurostimulation therapy for moderate to severe cases.
Inspire Medical Systems reported a 77% revenue growth in Q3 2022, reaching $109.2 million, driven by increased utilization and expansion of U.S. medical centers. The company activated 59 new centers, totaling 844 centers and launched new technologies enhancing patient experience. Despite a net loss of $16.8 million, the company raised its 2022 revenue guidance from $354-$362 million to $384-$388 million. However, European revenue faced challenges due to exchange rates, with a 14% decrease in international sales.
Inspire Medical Systems (NYSE: INSP) will announce its Q3 2022 financial results on November 1, following the market's close. Management will hold a conference call at 5:00 p.m. ET to discuss these results and recent business developments. Interested parties can register for the call via a provided link and access a live webcast on Inspire's Investor Relations page. Inspire specializes in minimally invasive solutions for obstructive sleep apnea, featuring its FDA-approved neurostimulation therapy.
Inspire Medical Systems, focusing on innovative treatments for obstructive sleep apnea, showcased advancements at the ISSS and AAO-HNSF meetings in Philadelphia from September 9-14, 2022. Highlights included the introduction of new 3D visualization software, enhancements in lead technology, and the Inspire SleepSync™ management platform. Clinical data presented showed high real-world efficacy of their treatments, particularly in a study analyzing surgical techniques and outcomes. Inspire remains committed to improving patient outcomes in sleep disorder treatment.
Inspire Medical Systems, focused on innovative solutions for obstructive sleep apnea, announced their participation at the Wells Fargo 2022 Healthcare Conference on September 8, 2022. The company's management will present at 3:10 p.m. ET at Encore Boston Harbor, Boston, MA. A live webcast of the presentation will be available and can be accessed via Inspire's investor website, along with a replay for two weeks post-event. Inspire offers the first FDA-approved neurostimulation technology targeting moderate to severe obstructive sleep apnea.
Inspire Medical Systems (NYSE: INSP) announced the appointment of Ezgi Yagci as Vice President of Investor Relations, effective August 15, 2022. Yagci brings over 15 years of experience from top-tier investment firms and was previously Investor Relations Manager at Zimmer Biomet. CEO Tim Herbert expressed confidence in her ability to enhance the company's investor relations program and contribute to its strategic goals. Yagci is eager to support Inspire's mission, particularly with anticipated product innovations for obstructive sleep apnea.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
